Curated news and analysis on clinical trials, drug approvals, and medical research.
Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.
Crohn’s disease is linked to kidney stones, dehydration and rare serious kidney complications. Monitoring, hydration and attention to medication-related risks can help protect kidney health.
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
German and Swiss pharmaceutical manufacturers warned that new US tariffs could threaten European production and research. Industry groups said the measures could disrupt medicine supply chains and shift investment to the US.
Experimental topical therapies for diabetic foot ulcers are showing early promise. Studies described probiotic-based treatments, a medieval antimicrobial mixture and a quercetin-loaded hyaluosome gel with anti-inflammatory and wound-healing effects.
A phase II clinical trial shows single-fraction stereotactic body radiation therapy with 30 Gy is as effective as three-fraction SBRT with 60 Gy for early-stage NSCLC. The study of 98 patients found no meaningful differences in survival, recurrence, or side effects between the two approaches. This could reduce costs and increase convenience for patients unable to undergo surgery.
The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
Recent studies reveal AI chatbots face significant challenges in medical applications, with one study showing ChatGPT Health under-triaged 51.6% of emergency cases. Cancer patients using an AI chatbot experienced 22% withdrawal rates due to usability issues, while medical researchers show cautious adoption with 40.3% reporting AI use in research.
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
Final phase 3 trial results show atrasentan (Vanrafia®) provides significant long-term kidney function benefits in IgA nephropathy patients, with a 2.59 mL/min/1.73m² eGFR improvement versus placebo. Earlier phase 2 data demonstrated the drug reduces proteinuria by 30.7% when added to standard background therapy. The drug's manufacturer plans to seek traditional FDA approval in 2026 based on these findings.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Analysis of 585 clinical trials reveals region is the primary driver of risk variation, with North America showing 29% higher screen failure rates. Heart failure trials show severe underrepresentation, with only 14.5% of participants from outside Europe and North America despite Asia having 50% of global heart failure cases. Central monitoring methods and representativeness indices are proposed to address these disparities.
MacroGenics faces critical 2026 milestones for its ADC pipeline, including Phase 1 data for MGC026 and regulatory resolution for lorigerlimab. The company has financial runway through 2027 and plans IND submission for MGC030 in Q3 2026. Key investor events include ASCO abstract releases and financial results in Q2 2026.
The ASCENT-04 trial shows Trodelvy plus Keytruda extends progression-free survival by 3.4 months in PD-L1-positive metastatic triple-negative breast cancer. Meanwhile, the ToPCourT trial investigates trilaciclib combined with pembrolizumab and chemotherapy for advanced TNBC. These developments signal evolving treatment approaches for this aggressive breast cancer subtype.
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
The FDA has granted orphan drug designation to Nuformix PLC's tranilast lysate candidate for treating idiopathic pulmonary fibrosis. The designation provides regulatory incentives including potential market exclusivity in the US. Nuformix is a London-based developer focused on fibrosis and oncology treatments.
Ocugen has completed enrollment and dosing in its phase II/III GARDian3 study for OCU410ST gene therapy targeting Stargardt disease. The study includes 63 patients and aims to address over 1,200 ABCA4 gene mutations with a single treatment. Interim data is expected in Q3 2026, with a BLA submission targeted for mid-2027.
Class action lawsuits allege securities violations by Atara Biotherapeutics and Inovio Pharmaceuticals related to FDA submissions. Atara faces claims over manufacturing issues with its tabelecleucel BLA, while Inovio is accused of misleading statements about INO-3107 regulatory timelines and manufacturing deficiencies.
